Targeting Small Molecule Delivery to the Brain and Spinal Cord via Intranasal Administration of Rabies Virus Glycoprotein (RVG29)-Modified PLGA Nanoparticles
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Alternative routes of administration are one approach that could be used to bypass the blood–brain barrier (BBB) for effective drug delivery to the central nervous system (CNS). Here, we focused on intranasal delivery of polymer nanoparticles. We hypothesized that surface modification of poly(lactic-co-glycolic acid) (PLGA) nanoparticles with rabies virus glycoprotein (RVG29) would increase residence time and exposure of encapsulated payload to the CNS compared to non-targeted nanoparticles. Delivery kinetics and biodistribution were analyzed by administering nanoparticles loaded with the carbocyanine dye 1,1′-Dioctadecyl-3,3,3′,3′-Tetramethylindotricarbocyanine Iodide (DiR) to healthy mice. Intranasal administration yielded minimal exposure of nanoparticle payload to most peripheral organs and rapid, effective delivery to whole brain. Regional analysis of payload delivery within the CNS revealed higher delivery to tissues closest to the trigeminal nerve, including the olfactory bulb, striatum, midbrain, brainstem, and cervical spinal cord. RVG29 surface modifications presented modest targeting benefits to the striatum, midbrain, and brainstem 2 h after administration, although targeting was not observed 30 min or 6 h after administration. Payload delivery to the trigeminal nerve was 3.5× higher for targeted nanoparticles compared to control nanoparticles 2 h after nanoparticle administration. These data support a nose-to-brain mechanism of drug delivery that closely implicates the trigeminal nerve for payload delivery from nanoparticles via transport of intact nanoparticles and eventual diffusion of payload. Olfactory and CSF routes are also observed to play a role. These data advance the utility of targeted nanoparticles for nose-to-brain drug delivery of lipophilic payloads and provide mechanistic insight to engineer effective delivery vectors to treat disease in the CNS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intranasal delivery of biologics to the central nervous system
Lochhead, J. J., & Thorne, R. G. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.002 · Cited by 1,214
Thorne, R. G., Pronk, G. J., Padmanabhan, V., & Frey, W. H. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.05.029 · Cited by 958
Pardeshi, C. V., & Belgamwar, V. S. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.790887 · Cited by 482
Insights into Direct Nose to Brain Delivery: Current Status and Future Perspective
Mittal, D., Ali, A., Md, S., Baboota, S., Sahni, J. K., & Ali, J. (2014) · Drug Delivery · doi:10.3109/10717544.2013.838713 · Cited by 359 · cited 1×
“For either the olfactory or trigeminal routes, access to the CSF is possible [31,32].”
BackgroundSurface-Modified Nanocarriers for Nose-To-Brain Delivery: From Bioadhesion to Targeting
Sonvico, F., Clementino, A. R., Buttini, F., Colombo, G., Pescina, S., Stanisçuaski Guterres, S., Raffin Pohlmann, A., & Nicoli, S. (2018) · doi:10.20944/preprints201802.0077.v1 · Cited by 306
Ross, T. M., Martinez, P. M., Renner, J. C., Thorne, R. G., Hanson, L. R., & Frey, W. H. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.02.011 · Cited by 242
Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer’s therapy
Rassu, G., Soddu, E., Posadino, A. M., Pintus, G., Sarmento, B., Giunchedi, P., & Gavini, E. (2017) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2017.01.031 · Cited by 239 · cited 1×
“Recent data published by Rassu and colleagues [43] specifically explored RVG29 complexed with siRNA for nose-to-brain delivery utilizing cellular assays, although in vivo delivery studies were not performed.”
Evidence of nose-to-brain delivery of nanoemulsions: Cargoes but not vehicles
Ahmad, E., Feng, Y., Qi, J., Fan, W., Ma, Y., He, H., Xia, F., Dong, X., Zhao, W., Lu, Y., et al. (2017) · Nanoscale · doi:10.1039/c6nr07581a · Cited by 194
Nose-To-Brain Delivery of PLGA-Diazepam Nanoparticles
Sharma, D., Sharma, R. K., Sharma, N., Gabrani, R., Sharma, S. K., Ali, J., & Dang, S. (2015) · AAPS PharmSciTech · doi:10.1208/s12249-015-0294-0 · Cited by 127 · cited 1×
“Polymeric nanoparticles are a popular material choice for drug delivery and have been shown to enhance CNS delivery of a drug relative to freely solubilized drug provided by the intranasal route [11,12].”
BackgroundFate of nanoparticles in the central nervous system after intrathecal injection in healthy mice
Householder, K. T., Dharmaraj, S., Sandberg, D. I., Wechsler-Reya, R. J., & Sirianni, R. W. (2019) · Scientific Reports · doi:10.1038/s41598-019-49028-w · Cited by 83 · cited 1×
“We have recently demonstrated that nanoparticles infused directly into cerebrospinal fluid (intrathecal injection via the cisterna magna) localize with dorsal root ganglia [30], whose exiting nerves would provide a direct pathway to skeletal muscle.”
BackgroundSelf-citation
Cited by
Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier
Zha, S., Liu, H., Li, H., Li, H., Wong, K.-L., & All, A. H. (2024) · ACS Nano · doi:10.1021/acsnano.3c10674 · Cited by 378
Wang, Q., Cheng, S., Qin, F., Fu, A., & Fu, C. (2021) · RSC Advances · doi:10.1039/d1ra00550b · Cited by 85
Wang, L., Shi, Y., Jiang, J., Li, C., Zhang, H., Zhang, X., Jiang, T., Wang, L., Wang, Y., & Feng, L. (2022) · Small · doi:10.1002/smll.202203678 · Cited by 71
Rufino-Ramos, D., Albuquerque, P. R., Leandro, K., Carmona, V., Martins, I. M., Fernandes, R., Henriques, C., Lobo, D., Faro, R., Perfeito, R., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.04.001 · Cited by 39
Metadata
- Authors
- Chung, E. P., Cotter, J. D., Prakapenka, A. V., Cook, R. L., DiPerna, D. M., & Sirianni, R. W.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2020-01-24
- Volume
- 12
- Issue
- 2
- Pages
- 93
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W3001621435
- Cited by
- 69
- References
- 10
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.